Compare Stocks: LYEL, CRVS, SVRA, and MLTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$12.56 +0.1%	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	823,602 shs	4.46 million shs
LYEL Lyell Immunopharma	$11.01 +1.9%	$13.63	$10.46 ▼ $45.00	$264.65M	-0.04	93,967 shs	401,120 shs
MLTX MoonLake Immunotherapeutics	$12.39 +0.3%	$16.55	$5.95 ▼ $62.75	$1.05B	1.04	1.35 million shs	1.80 million shs
SVRA Savara	$5.37 -0.9%	$5.49	$3.34 ▼ $7.01	$1.11B	0.25	1.34 million shs	2.18 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	+0.08%	-2.71%	-18.44%	+5.46%	+116.93%
LYEL Lyell Immunopharma	+1.94%	-7.94%	-30.14%	-13.58%	-10.56%
MLTX MoonLake Immunotherapeutics	+0.32%	-0.96%	-25.99%	-35.50%	-75.79%
SVRA Savara	-0.92%	+1.32%	-3.76%	-2.36%	+49.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$12.56 +0.1%	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	823,602 shs	4.46 million shs
LYEL Lyell Immunopharma	$11.01 +1.9%	$13.63	$10.46 ▼ $45.00	$264.65M	-0.04	93,967 shs	401,120 shs
MLTX MoonLake Immunotherapeutics	$12.39 +0.3%	$16.55	$5.95 ▼ $62.75	$1.05B	1.04	1.35 million shs	1.80 million shs
SVRA Savara	$5.37 -0.9%	$5.49	$3.34 ▼ $7.01	$1.11B	0.25	1.34 million shs	2.18 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	+0.08%	-2.71%	-18.44%	+5.46%	+116.93%
LYEL Lyell Immunopharma	+1.94%	-7.94%	-30.14%	-13.58%	-10.56%
MLTX MoonLake Immunotherapeutics	+0.32%	-0.96%	-25.99%	-35.50%	-75.79%
SVRA Savara	-0.92%	+1.32%	-3.76%	-2.36%	+49.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	165.39% Upside
LYEL Lyell Immunopharma	2.78	Moderate Buy	$40.86	271.09% Upside
MLTX MoonLake Immunotherapeutics	2.44	Hold	$24.57	98.32% Upside
SVRA Savara	2.88	Moderate Buy	$10.00	86.22% Upside

Current Analyst Ratings Breakdown

Latest LYEL, CRVS, SVRA, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/11/2026	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	LYEL Lyell Immunopharma	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	LYEL Lyell Immunopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/14/2026	LYEL Lyell Immunopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/7/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	LYEL Lyell Immunopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
7/30/2026	CRVS Corvus Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	99.01	$0.73 per share	N/A
LYEL Lyell Immunopharma	$40K	6,743.63	N/A	N/A	$11.68 per share	0.94
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
LYEL Lyell Immunopharma	-$274.45M	-$12.83	N/A	N/A	N/A	-920,285.25%	-91.62%	-70.50%	11/10/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest LYEL, CRVS, SVRA, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A
8/6/2026	Q2 2026	LYEL Lyell Immunopharma	-$1.94	-$1.9180	+$0.0220	-$1.92	$0.00 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
LYEL Lyell Immunopharma	N/A	5.36	5.36
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
LYEL Lyell Immunopharma	66.05%
MLTX MoonLake Immunotherapeutics	93.85%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	19.70%
LYEL Lyell Immunopharma	6.20%
MLTX MoonLake Immunotherapeutics	10.40%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
LYEL Lyell Immunopharma	161	24.50 million	22.99 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

LYEL, CRVS, SVRA, and MLTX Headlines

Recent News About These Companies

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18 at 4:13 AM | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Savara Inc. $SVRA

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

September 3, 2026 | marketbeat.com

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

August 31, 2026 | marketbeat.com

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Savara (SVRA) Gets a Buy from Piper Sandler

July 24, 2026 | theglobeandmail.com

Here's Why You Should Add Savara Stock to Your Portfolio Now

July 22, 2026 | zacks.com

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

June 27, 2026 | fool.com

What Is Driving Attention Toward Savara’s Rare Disease Strategy?

June 15, 2026 | kalkinemedia.comK

Savara Announces New Employment Inducement Grant

June 12, 2026 | businesswire.com

Savara Announces Chief Financial and Administrative Officer Transition

June 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, CRVS, SVRA, and MLTX Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$12.56 +0.01 (+0.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.50 -0.06 (-0.51%)

As of 09/18/2026 07:56 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Lyell Immunopharma NASDAQ:LYEL

$11.01 +0.21 (+1.94%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.99 -0.02 (-0.18%)

As of 09/18/2026 07:30 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$12.39 +0.04 (+0.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.36 -0.03 (-0.20%)

As of 09/18/2026 07:53 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Savara NASDAQ:SVRA

$5.37 -0.05 (-0.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.44 +0.06 (+1.21%)

As of 09/18/2026 07:30 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, CRVS, SVRA, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, CRVS, SVRA, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, CRVS, SVRA, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, CRVS, SVRA, and MLTX Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Lyell Immunopharma NASDAQ:LYEL

MoonLake Immunotherapeutics NASDAQ:MLTX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, CRVS, SVRA, and MLTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, CRVS, SVRA, and MLTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, CRVS, SVRA, and MLTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, CRVS, SVRA, and MLTX Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Lyell Immunopharma NASDAQ:LYEL

MoonLake Immunotherapeutics NASDAQ:MLTX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools